Functional recovery after wharton’s jelly-derived mesenchymal stem cell administration in a patient with traumatic brain injury: a pilot study

AIM Traumatic brain injury (TBI) is described as brain parenchyma damage that results in neurological impairment after a trauma. It can cause a main insult accompanied by a series of secondary insults. The primary injury may be repaired through surgical operation, however, there are only limited options for managing the secondary insults. Stem cell transplantation (SCT) became an innovative method of treatment in TBI, since it can halt degeneration and support the renovation of the damaged brain cells. MATERIAL AND METHODS This study included a 29 years old male who had TBI resulting from a vehicle accident which took place one and a half years ago. The participant received six doses of intrathecal, intramuscular, and intravenous transplantation of WJ-MSCs at a goal dose of lxl06 / kg respectively for each route of administration for six months Results: No important negative effects were reported. The patients' speech, cognitive, memory and fine motor skills were improved. The efficacy of treatment with SCT was assessed with cranial magnetic resonance imaging (MRI), computed tomography (CT) screening, and electroencephalography (EEG). CONCLUSION SCT can have a promising future as a medical approach in recurrent TBI.